CIBC Asset Management Inc lifted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 58,871 shares of the medical instruments supplier's stock after purchasing an additional 1,948 shares during the quarter. CIBC Asset Management Inc's holdings in Becton, Dickinson and Company were worth $13,348,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after acquiring an additional 877 shares in the last quarter. E. Ohman J or Asset Management AB grew its holdings in Becton, Dickinson and Company by 13.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier's stock valued at $39,951,000 after buying an additional 20,859 shares during the last quarter. Arete Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $767,000. Busey Bank grew its holdings in shares of Becton, Dickinson and Company by 3.8% during the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier's stock worth $15,031,000 after purchasing an additional 2,399 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier's stock worth $720,089,000 after buying an additional 1,317,723 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.
Becton, Dickinson and Company Stock Performance
NYSE:BDX traded down $0.39 on Friday, hitting $227.54. The company's stock had a trading volume of 1,920,647 shares, compared to its average volume of 2,087,390. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The stock has a fifty day moving average of $232.86 and a two-hundred day moving average of $233.34. The firm has a market capitalization of $65.34 billion, a P/E ratio of 37.80, a price-to-earnings-growth ratio of 1.63 and a beta of 0.40. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a $1.04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.83%. Becton, Dickinson and Company's payout ratio is 69.10%.
Becton, Dickinson and Company announced that its Board of Directors has approved a share repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the company. Barclays lifted their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Piper Sandler boosted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a research note on Tuesday, January 28th. Finally, StockNews.com raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, February 12th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company has a consensus rating of "Buy" and an average price target of $278.29.
Read Our Latest Report on Becton, Dickinson and Company
Insider Activity
In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the transaction, the executive vice president now directly owns 24,345 shares of the company's stock, valued at approximately $5,380,488.45. The trade was a 15.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bertram L. Scott sold 700 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the transaction, the director now directly owns 36,033 shares in the company, valued at $8,215,163.67. The trade was a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,544 shares of company stock worth $2,370,309. Insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
